Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

You searched for:

Ochsner Health employed a new type of artificial intelligence and natural language processing to improve its capacity to screen patients for clinical trials.
NCOA ONCOLOGY DRUG NEWSLETTER D E C E M B E R 2 0 2 3 This content is being shared with permission from MJH Life Sciences. All content of Targeted Oncology is independently created and owned by MJH Life Sciences. FDA APPROVALS Capivasertib (Truqap) and Fulvestrant (Faslodex) Combination The FDA granted approval to the combination of capivasertib (Truqap) and fulvestrant …
NCOA ONCOLOGY DRUG NEWSLETTER D E C E M B E R 2 0 2 3 This content is being shared with permission from MJH Life Sciences. All content of Targeted Oncology is independently created and owned by MJH Life Sciences. FDA APPROVALS Capivasertib (Truqap) and Fulvestrant (Faslodex) Combination The FDA granted approval to the combination of capivasertib (Truqap) and fulvestrant …
TxSCO ONCOLOGY DRUG NEWSLETTER D E C E M B E R 2 0 2 3 This content is being shared with permission from MJH Life Sciences. All content of Targeted Oncology is independently created and owned by MJH Life Sciences. FDA APPROVALS Capivasertib (Truqap) and Fulvestrant (Faslodex) Combination The FDA granted approval to the combination of capivasertib (Truqap) and fulvestrant …
TACOS ONCOLOGY DRUG NEWSLETTER D E C E M B E R 2 0 2 3 This content is being shared with permission from MJH Life Sciences. All content of Targeted Oncology is independently created and owned by MJH Life Sciences. FDA APPROVALS Capivasertib (Truqap) and Fulvestrant (Faslodex) Combination The FDA granted approval to the combination of capivasertib (Truqap) and fulvestrant …
Managing Continuous Change Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=uacc20 Oncology Issues ISSN: 1046-3356 (Print) 2573-1777 (Online) Journal homepage: https://www.tandfonline.com/loi/uacc20 Managing Continuous Change Donald Jewler & Cara Egan To cite this article: Donald Jewler & Cara Egan …
JF07-Innovative-Ideas
MJ12-Nicole's-Oncofertility-Toolkit
Florida Hospital Cancer Institute Memorial Medical Center Daytona Beach, Florida 2 Purpose and Background .........................................................................................3 Site …
Trends-in-Cancer-Programs-2016
FAN-Advanced-Directives
Improving Non-Small Cell Lung Cancer Care Delivery: Findings for Oncology Nurses and Patient Navigation From a National Quality Survey Jennifer Aversano, MSN, RN, OCN, BMTCN1; Leigh M. Boehmer, PharmD, BCOP2; Alexander Spira, MD, PhD, FACP3,4,5 1Advocate Lutheran General Hospital, Park Ridge, Illinois, USA; 2Association of Community Cancer Centers, Rockville, Maryland, USA; 3Virginia Cancer …
TxSCO ONCOLOGY DRUG NEWSLETTER N O V E M B E R 2 0 2 3 This content is being shared with permission from MJH Life Sciences. All content of Targeted Oncology is independently created and owned by MJH Life Sciences. FDA APPROVALS Pembrolizumab (Keytruda) The FDA has approved perioperative pembrolizumab (Keytruda) in combination with platinum-containing chemotherapy as neoadjuvant treatment …
TACOS ONCOLOGY DRUG NEWSLETTER N O V E M B E R 2 0 2 3 This content is being shared with permission from MJH Life Sciences. All content of Targeted Oncology is independently created and owned by MJH Life Sciences. FDA APPROVALS Pembrolizumab (Keytruda) The FDA has approved perioperative pembrolizumab (Keytruda) in combination with platinum-containing chemotherapy as neoadjuvant treatment …
SCOS ONCOLOGY DRUG NEWSLETTER N O V E M B E R 2 0 2 3 This content is being shared with permission from MJH Life Sciences. All content of Targeted Oncology is independently created and owned by MJH Life Sciences. FDA APPROVALS Pembrolizumab (Keytruda) The FDA has approved perioperative pembrolizumab (Keytruda) in combination with platinum-containing chemotherapy as neoadjuvant treatment …
NCOA ONCOLOGY DRUG NEWSLETTER N O V E M B E R 2 0 2 3 This content is being shared with permission from MJH Life Sciences. All content of Targeted Oncology is independently created and owned by MJH Life Sciences. FDA APPROVALS Pembrolizumab (Keytruda) The FDA has approved perioperative pembrolizumab (Keytruda) in combination with platinum-containing chemotherapy as neoadjuvant treatment …
PowerPoint Presentation Updates from Capitol Hill: What to look for in 2023 Jennifer Brunelle Chief Advocacy Officer February 17, 2023 Disclosure of Conflicts of Interest Jennifer Brunelle has no relevant financial relationships to disclose. ASCO and State Affiliates: Partners in Advocacy • Sign-on letters to Congress • Meetings with federal & state …
Bladder Sparing Therapies for Urothelial Cancer: A Radiation Oncolgist’s Perspective BLADDER SPARING THERAPIES FOR UROTHELIAL CANCER: A RADIATION ONCOLOGIST’S PERSPECTIVE MINNESOTA SOCIETY OF CLINICAL ONCOLOGY 2024 SPRING CONFERENCE, 04/24/2024 OUTLINE • INTRODUCTION • WORKUP, STAGING • DEFINITIVE MANAGEMENT OPTIONS • BLADDER PRESERVATION PRINCIPLES • CASES AND CONTROVERSIES …
Creating a Resilient, Results-Driven Oncology Team Vicki Hess, author and Principal, Employee Engagement Solutions, LLC Learn how to become a “Chief Paradise Officer” at your cancer program or oncology practice by taking five steps to improve your resiliency, energy, and results. Author of four books, including SHIFT to Professional Paradise, Vicki will inspire you to action by sharing high …
1 \\DC - 099654/000003 - 14359301 v8 Overview of Selected Provisions of the Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System Proposed Rule for Calendar Year 2020 On August 9, 2019, the Centers for Medicare & Medicaid Services (CMS) published the Hospital Outpatient Prospective Payment (OPPS) and …